SENSEX, NIFTY50 end lower as rising crude oil dents investor sentiment

The Indian equity benchmarks ended lower on Tuesday, August 11, as investor sentiment took a knock after crude oil prices surged in global markets on growing concerns over reopening of the Strait of Hormuz. The SENSEX fell as much as 494 points and NIFTY50 index touched an intraday low of 24,429 dragged down by losses in index heavyweights like Bharti Airtel, Axis Bank, HDFC Bank, Larsen & Toubro, Reliance Industries and Bajaj Finance.

The SENSEX dropped 388 points to close at 78,154 and NIFTY50 index declined 112 points to settle at 24,471.

Brent crude oil futures rose as much as 2.63% to hit an intraday high of $90 per barrel raising concerns for investors as ongoing disruption to Middle East energy flows and fading hopes for a peace deal between US and Iran heightened worries for global oil supplies.

Nine of 15 major sector gauges compiled by the National Stock Exchange (NSE) ended lower led by the NIFTY FMCG index's 1.2% fall. NIFTY Bank, Financial Services, Auto, Metal, Private Bank and Realty indices also fell between 0.4% and 1%.

On the other hand, IT, pharma, healthcare, consumer durables and oil & gas shares witnessed a mild buying interest.

Broader markets ended on a mixed note as NIFTY Midcap 100 index ended on marginally lower while NIFTY Smallcap index rose 0.2%.

Among the individual shares, Gland Pharma rose as much as 12% to hit a fresh 52-week high of ₹2,989.25 on the BSE after it reported its June quarter earnings.

Gland Pharma's net profit in April-June period rose 47% annually to ₹317 crore from ₹215 crore a year earlier.

The company’s revenue from core operations advanced 19.5% to ₹1,800 crore in the June quarter from ₹1,506 crore in the same period a year earlier.

The revenue growth was largely due to the strong performance in the US market segment, where revenue surged 32% YoY to ₹981 crore, and around 20% in Europe to ₹395 crore.

Zydus Lifesciences advanced as much as 7.68% to hit an intraday high of ₹1,205 after its net profit rose 35.93% year-on-year (YoY) fall in its consolidated net profit to ₹939.8 crore.

The pharma major’s revenue from operations jumped 20.74% YoY to ₹8,123.1 crore during the quarter under review, compared with ₹6,728.6 crore in the first quarter of the 2025-26 fiscal year (Q1 FY26).

The firm’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) declined 7.6% YoY to ₹1,929.4 crore in the June quarter of FY27, as against ₹2,088.5 crore in the year-ago period.

Tata Consumer Products was top loser in the NIFTY50 index, the stock rose 2.77% to close at ₹1,078. Max Healthcare, Nestle India, Ultratech Cement, Apollo Hospitals, Grasim, Mahindra & Mahindra, Bharti Airtel and JSW Steel also fell between 1.4% and 2.7%.

On the flip side, Dr Reddy's Labs, Eternal, TCS, Titan, Infosys, HCL Tech, Bajaj Finserv, Coal India and Bharat Electronics were top gainers in the NIFTY50 index.

The overall market breadth was negative as 1,867 shares ended lower while 1,487 ended higher on the NSE.